NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
29/07/2025
Voltar para busca
Dado oficial do USPTO
SYNAPSE MED
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
29/07/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
9, 42, 44
Data de depósito
08/10/2021
Data de registro
29/07/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/07/2025
Última transação
29/07/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Primeiro uso
2020-06-00
Primeiro uso no comércio
2020-07-00
Código do desenho
5
Tipo de titular
99
Localização do titular
33000, FR
Examinador
LE, KIEU-NHI NGOC
Unidade examinadora
O20
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "SYNAPSE" in blue with the wording "MED" in blue superscripted to the right of the "E" in "SYNAPSE".
Titulares e representantes
Titulares
S. M. (pessoa física)
Representantes
Todd A. Denys Mandelbaum Barrett PC
Classificação técnica
Classes Nice
Classe 9Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable computer software using artificial intelligence for medical prescription assistancesoftware for word processing and establishing standardized directories; Downloadable computer software using artificial intelligence to avoid medical risks and contraindications and for drug interaction preventionsoftware for word processing and establishing standardized directories; Downloadable computer software using artificial intelligence for medical prescriptions analysissoftware for word processing and establishing standardized directories; none of the above products are for use or provided in the field of medical informatics management and image recognitionAI platforms in the medical field
Classe 42
Research in the field of artificial intelligence for computer software design for medical prescription assistancefor the prevention of medicinal riskscontraindications and drug interactions; Research in the field of artificial intelligence for computer software design for prescription analysis; Software design and development for medical prescription assistancefor the prevention of medicinal riskscontraindications and drug interactions; Software design and development for prescription analysis; Software as a service (SAAS) services featuring software using artificial intelligence for word processing and establishing standardized directories in the fields of medical prescription assistancefor the prevention of medicinal riskscontraindications and drug interactions; Software as a service (SAAS) services featuring software using artificial intelligence for word processing and establishing standardized directories for prescription analysis; none of the above services are for use or provided in the field of medical informatics management and image recognitionAI platforms in the medical field; Software as a service (SAAS) services featuring software modules for providing prescription assistance through telemedicine platforms
Classe 44
Telemedicine services; Prescription assistance modules in the nature of providing information in the field of medical prescriptions via telemedicine platforms; Providing advice relating to medical services provided via telecommunications technology; providing information in the field of telemedicine; providing information in the field of medical prescription; providing information in the field of medical prescription analysis; none of the above services are for use or provided in the field of medical informatics management and image recognitionAI platforms in the medical field
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
29/07/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
16/07/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
16/07/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
16/07/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
16/07/2025
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
16/07/2025
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
07/07/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
07/06/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/06/2025
IUAF
USE AMENDMENT FILED
10/03/2025
EISU
TEAS STATEMENT OF USE RECEIVED
10/03/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
10/09/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
16/07/2024
PUBO
PUBLISHED FOR OPPOSITION
16/07/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
26/06/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/06/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
07/06/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
07/06/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
07/06/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
07/06/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/05/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/05/2024
ALIE
ASSIGNED TO LIE
06/05/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/04/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
17/04/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/04/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/04/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
17/04/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
17/04/2024
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
14/12/2023
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
14/09/2023
GNSI
INQUIRY TO SUSPENSION E-MAILED
14/09/2023
CNSI
SUSPENSION INQUIRY WRITTEN
14/09/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
16/02/2023
GNSL
LETTER OF SUSPENSION E-MAILED
16/02/2023
CNSL
SUSPENSION LETTER WRITTEN
16/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/01/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/01/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/07/2022
GNRT
NON-FINAL ACTION E-MAILED
14/07/2022
CNRT
NON-FINAL ACTION WRITTEN
14/07/2022
DOCK
ASSIGNED TO EXAMINER
13/07/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/11/2021
NWAP
NEW APPLICATION ENTERED
12/10/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SYNAPSE MED ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.